Sysmex

Skip Navigation

SearchMenu

About Sysmex

Press Releases

Products & Solution Products & Solution
Apr. 13, 2012

Sysmex and Roche renew successful alliance in the hematology business
- Distributorship, sales and services agreement extends for another 10 years -

  Sysmex Corporation (HQ: Kobe, Japan; President and CEO: Hisashi Ietsugu) and Roche Diagnostics Ltd. (SIX: RO, ROG; OTCQX: RHHBY) today announced the signing of a restated 10 years distribution, sales and services agreement (“DSS Agreement”). Under the agreement, Roche will continue to distribute the Sysmex hematology products, including instruments, reagents and data management solutions in selected countries and regions1.

  Since entering into the DSS Agreement in 1999, Sysmex and Roche have applied their mutual strengths to expand market share while building a favorable relationship.


  “Based on Sysmex’ industry leadership allied with Roche’s unique position as the global market leader in in vitro diagnostics, the collaboration underlines our objective of bringing a maximum of industry expertise in hematology to health professionals. This unique synergy supports both companies’ objectives to continue to grow above market”, comments Hisashi Ietsugu, President and CEO of Sysmex Corporation.


  The recently released new XN series from Sysmex with its modular and scalable system design addresses customer needs for access to a full menu across customer segments from small to large workloads. Concurrent with Roche’s future platform strategy, the new Sysmex XN series contributes to Roche’s concept of addressing the various needs of today’s laboratories with customized modular solutions. The renewed agreement allows both companies to apply their strengths more effectively.


  “The breadth of the Sysmex portfolio combined with Roche’s cobas® analyzer platforms allows customers to choose from the broadest set of instruments available for each laboratory setting. This embraces our goal to strengthen and to expand Roche’s offering in central laboratories in hospitals and commercial laboratories”, states Colin Brown, Head of Roche Professional Diagnostics, Roche’s market-leading business area of integrated, modular and highly-efficient testing solutions for clinical and immuno in-vitro diagnostics for centralised and decentralised settings.



Reference

1) Territories include Spain, Turkey, Greece, South Africa, Russia, Finland, Baltic Territory, Brazil, Mexico, Chile, Argentina, Uruguay, Colombia, Peru, Ecuador, Venezuela, Central America, Australia and New Zealand.



About Sysmex Corporation

Sysmex Corporation, based in Kobe, Japan, is a world leader in the clinical laboratory testing of blood, urine and other specimens, providing instruments and reagents for clinical laboratory testing as well as laboratory information systems as part of a comprehensive service and support system.

Founded in 1968 as a company specializing in hematology, Sysmex Corporation has expanded to offer a comprehensive range of products and solutions in the diagnostic field including hemostasis, immunochemistry, clinical chemistry, urinalysis, point-of-care and other disciplines. The company is also actively involved in developing new advanced technologies in the Life Science field to offer total healthcare solutions to people throughout the world. For more information about Sysmex, please visit http://www.sysmex.co.jp/en/.



About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com/.

*Information contained in the press release is current as of the date of the announcement,
but may be subject to change without prior notice.

Back to "Press Releases"